Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of rilvegostomig-based combinations versus trastuzumab + chemotherapy + pembrolizumab in HER2-positive gastric or gastroesophageal junction adenocarcinoma
NL-OMON60911Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of rilvegostomig, trastuzumab deruxtecan, trastuzumab, pembrolizumab, fluorouracil and 3 more in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (3 arms), sponsored by AstraZeneca. Primary endpoints: Progression-free Survival and Overall Survival. Started Oct 2025; status: recruiting.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NL-OMON60911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60911.